JP2010530359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530359A5 JP2010530359A5 JP2010508353A JP2010508353A JP2010530359A5 JP 2010530359 A5 JP2010530359 A5 JP 2010530359A5 JP 2010508353 A JP2010508353 A JP 2010508353A JP 2010508353 A JP2010508353 A JP 2010508353A JP 2010530359 A5 JP2010530359 A5 JP 2010530359A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- nrp1
- nrp2
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 47
- 101150106321 Nrp2 gene Proteins 0.000 claims description 37
- 101150051337 NRP1 gene Proteins 0.000 claims description 36
- 239000005557 antagonist Substances 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 32
- 239000013078 crystal Substances 0.000 claims description 31
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 28
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 28
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 28
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 16
- 230000005855 radiation Effects 0.000 claims description 16
- 108050003978 Semaphorin Proteins 0.000 claims description 14
- 102000014105 Semaphorin Human genes 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 12
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 230000004071 biological effect Effects 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 6
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 6
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 6
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 6
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 6
- 229960000241 vandetanib Drugs 0.000 claims description 6
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102000004207 Neuropilin-1 Human genes 0.000 claims description 4
- 108090000772 Neuropilin-1 Proteins 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- BRVFNEZMTRVUGW-QFIPXVFZSA-N (2s)-2-[6-[(3-methyl-1-oxo-4h-benzo[f]quinazolin-9-yl)methylamino]-3-oxo-1h-isoindol-2-yl]pentanedioic acid Chemical compound C1=C2C(=O)N([C@@H](CCC(O)=O)C(O)=O)CC2=CC(NCC2=CC=C3C=CC4=C(C3=C2)C(=O)N=C(N4)C)=C1 BRVFNEZMTRVUGW-QFIPXVFZSA-N 0.000 claims description 3
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims description 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 3
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 claims description 3
- 229960005557 OSI-7904 Drugs 0.000 claims description 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 3
- 229960002412 cediranib Drugs 0.000 claims description 3
- 229960001433 erlotinib Drugs 0.000 claims description 3
- 229960002584 gefitinib Drugs 0.000 claims description 3
- 229940080856 gleevec Drugs 0.000 claims description 3
- 229960002411 imatinib Drugs 0.000 claims description 3
- 229960004891 lapatinib Drugs 0.000 claims description 3
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 3
- 229950010895 midostaurin Drugs 0.000 claims description 3
- RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 claims description 3
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims description 3
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 3
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- 229960001796 sunitinib Drugs 0.000 claims description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 3
- 229940034785 sutent Drugs 0.000 claims description 3
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 claims description 3
- 229940120982 tarceva Drugs 0.000 claims description 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims description 3
- 229940099039 velcade Drugs 0.000 claims description 3
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 229940119473 Semaphorin antagonist Drugs 0.000 claims description 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000010807 negative regulation of binding Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229960003876 ranibizumab Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 229950000578 vatalanib Drugs 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2007/069185 WO2008143666A2 (en) | 2007-05-17 | 2007-05-17 | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012180233A Division JP5207564B2 (ja) | 2012-08-15 | 2012-08-15 | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
| JP2012180232A Division JP5723840B2 (ja) | 2012-08-15 | 2012-08-15 | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530359A JP2010530359A (ja) | 2010-09-09 |
| JP2010530359A5 true JP2010530359A5 (https=) | 2011-05-12 |
Family
ID=38963109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010508353A Withdrawn JP2010530359A (ja) | 2007-05-17 | 2007-05-17 | ニューロピリンのフラグメントおよびニューロピリン−抗体複合体の結晶構造 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8318163B2 (https=) |
| EP (1) | EP2158215B1 (https=) |
| JP (1) | JP2010530359A (https=) |
| KR (1) | KR101523788B1 (https=) |
| CN (1) | CN101743253B (https=) |
| AU (1) | AU2007353779B2 (https=) |
| BR (1) | BRPI0721707A2 (https=) |
| CA (1) | CA2687556A1 (https=) |
| ES (1) | ES2541051T3 (https=) |
| IL (1) | IL201983A (https=) |
| MX (1) | MX2009012282A (https=) |
| RU (1) | RU2012109383A (https=) |
| WO (1) | WO2008143666A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| RU2577986C2 (ru) * | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Антитела против axl и способы их применения |
| CN103561771B (zh) | 2011-03-17 | 2019-01-04 | 伯明翰大学 | 重新定向的免疫治疗 |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| CN103992376B (zh) * | 2013-02-18 | 2017-05-17 | 上海市第一人民医院 | 一种抑制新生血管的小肽及其应用 |
| CN103992377B (zh) * | 2013-02-18 | 2017-05-17 | 上海市第一人民医院 | 一种抑制新生血管的小肽及其应用 |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| EP3148564B1 (en) | 2014-06-02 | 2020-01-08 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
| RS61703B1 (sr) * | 2014-09-05 | 2021-05-31 | Rsem Limited Partnership | Kompozicije i postupci za lečenje i prevenciju zapaljenja |
| KR102293753B1 (ko) | 2016-01-06 | 2021-08-24 | 오더-메이드 메디컬 리서치 인코포레이티드 | Vegf 와 nrp1 의 결합을 저해하는 항체 |
| US11007259B2 (en) | 2016-01-06 | 2021-05-18 | Order-Made Medical Research Inc. | High-affinity anti-VEGF antibody |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| JOP20190134A1 (ar) * | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
| CA3060514A1 (en) | 2017-04-20 | 2018-10-25 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| KR20200026209A (ko) * | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 |
| AU2019247511B2 (en) * | 2018-04-06 | 2025-10-16 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| TWI859339B (zh) | 2019-09-24 | 2024-10-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
| CA3156803A1 (en) | 2019-10-03 | 2021-04-08 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| GB202207116D0 (en) * | 2022-05-16 | 2022-06-29 | Quadram Inst Bioscience | Method and Compositions for Tumorigenesis Inhibition |
| CN114949224B (zh) * | 2022-06-06 | 2023-03-14 | 山东大学第二医院 | Nrp2激动剂在制备复发性流产治疗药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0397834B1 (en) * | 1988-10-28 | 2000-02-02 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| CA2095633C (en) * | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ATE414768T1 (de) * | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
| ES2156149T3 (es) * | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| PT971959E (pt) | 1997-04-07 | 2006-05-31 | Genentech Inc | Anticorpos humanizados e metodos para formar anticorpos humanizados |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2007
- 2007-05-17 KR KR1020097026233A patent/KR101523788B1/ko not_active Expired - Fee Related
- 2007-05-17 JP JP2010508353A patent/JP2010530359A/ja not_active Withdrawn
- 2007-05-17 AU AU2007353779A patent/AU2007353779B2/en not_active Ceased
- 2007-05-17 EP EP20070762242 patent/EP2158215B1/en active Active
- 2007-05-17 CA CA002687556A patent/CA2687556A1/en not_active Abandoned
- 2007-05-17 ES ES07762242.1T patent/ES2541051T3/es active Active
- 2007-05-17 WO PCT/US2007/069185 patent/WO2008143666A2/en not_active Ceased
- 2007-05-17 CN CN2007800537931A patent/CN101743253B/zh not_active Expired - Fee Related
- 2007-05-17 BR BRPI0721707-2A patent/BRPI0721707A2/pt not_active IP Right Cessation
- 2007-05-17 US US12/598,625 patent/US8318163B2/en not_active Expired - Fee Related
- 2007-05-17 MX MX2009012282A patent/MX2009012282A/es active IP Right Grant
-
2009
- 2009-11-08 IL IL201983A patent/IL201983A/en not_active IP Right Cessation
-
2012
- 2012-03-12 RU RU2012109383/10A patent/RU2012109383A/ru not_active Application Discontinuation
- 2012-07-03 US US13/541,411 patent/US8466264B2/en not_active Expired - Fee Related